4.5 Article

Patients with Rheumatoid Arthritis in Clinical Remission Manifest Persistent Joint Inflammation on Histology and Imaging Studies

期刊

JOURNAL OF RHEUMATOLOGY
卷 41, 期 11, 页码 2153-2160

出版社

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.140411

关键词

RHEUMATOID ARTHRITIS; REMISSION; HISTOLOGY; MAGNETIC RESONANCE IMAGING; ULTRASOUND

向作者/读者索取更多资源

Objective. The purpose of our study was to test the hypothesis that synovitis on magnetic resonance imaging (MRI) and ultrasound (US) observed in patients with rheumatoid arthritis (RA) who meet remission criteria reflects active inflammation on histopathology. Methods. We analyzed 15 synovial specimens obtained during surgical procedures from 14 patients with RA in clinical remission as defined by the American College of Rheumatology criteria. Histological specimens were scored for hyperplasia of synovial lining and synovial stroma, inflammation, lymphoid follicles, and vascularity. The histology scores were classified as minimal, mild, moderate, or severe disease activity. US and MRI performed within a 4-month period of surgery were scored for disease activity. The correlation between histology and imaging scores was examined. Results. Four of 14 patients were receiving anti-tumor necrosis factor (TNF) therapy, 4 were receiving methotrexate (MTX) alone, 4 were taking MTX and hydroxychloroquine (HCQ), and 1 was taking HCQ and sulfasalazine. Four specimens had severe, 6 moderate, 3 mild, and 2 minimal disease activity on histology. Three of 4 specimens with minimal and mild histology were observed in subjects receiving anti-TNF therapy. Synovitis was noted on greyscale in 80% of joints and Doppler signal in 60%. MRI demonstrated synovitis and bone marrow edema in 86% of images. Positive but not significant correlations were noted between histology and synovitis scores on US. Conclusion. Despite clinical remission, histology and imaging studies documented a persistently active disease state that may explain the mechanism for radiographic progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Identification and Characterization of a High-Need, High-Cost Group Among Hospitalized Patients With Systemic Lupus Erythematosus

Allen Anandarajah, Caroline Thirukumaran, Katherine McCarthy, Sean McMahon, Changyong Feng, Christopher Ritchlin

Summary: By studying a group of high-need, high-cost patients with lupus, researchers found that these patients accounted for the majority of hospitalizations and medical costs. The clinical and social factors of this group were significantly different from other lupus patients, particularly in terms of blood indicators and social backgrounds.

ARTHRITIS CARE & RESEARCH (2022)

Review Immunology

Navigating the diverse immune landscapes of psoriatic arthritis

Christopher Ritchlin

Summary: This article discusses the plasticity of the immune response in PsA, focusing on the importance of therapeutic targets including Th17 cells, monocytes, and CD8+ T resident cells. Additionally, it examines the effects of cytokines on tissue populations and new data on the interaction between immune cells and tissue resident cells in PsA.

SEMINARS IN IMMUNOPATHOLOGY (2021)

Review Dermatology

New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine

Di Yan, Johann E. Gudjonsson, Stephanie Le, Emanual Maverakis, Olesya Plazyo, Christopher Ritchlin, Jose U. Scher, Roopesh Singh, Nicole L. Ward, Stacie Bell, Wilson Liao

Summary: Psoriasis is a chronic inflammatory condition characterized by systemic immune dysregulation. Recent advances in genetics, microbiology, immunology, and mouse models have shed light on the complex interplay between heritable and microenvironmental factors in driving psoriatic inflammation. These scientific advancements have paved the way for a more personalized approach to treating psoriatic disease.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Article Rheumatology

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis

Effie Pournara, Matthias Kormaksson, Peter Nash, Christopher T. Ritchlin, Bruce W. Kirkham, Gregory Ligozio, Luminita Pricop, Alexis Ogdie, Laura C. Coates, Georg Schett, Iain B. McInnes

Summary: Distinct clusters of PsA patients were identified based on their baseline disease manifestations, with varying responses to secukinumab doses observed across different clusters. The study highlights the potential of machine learning in predicting patient outcomes based on PsA clusters.

RMD OPEN (2021)

Article Rheumatology

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies

Christopher T. Ritchlin, Philip J. Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar

Summary: The study evaluated the efficacy of guselkumab in PsA patients and found that both Q4W and Q8W treatments resulted in robust and sustained improvements in signs and symptoms across subgroups defined by diverse baseline characteristics.

RMD OPEN (2022)

Article Rheumatology

Dysregulation of Bile Acids, Lipids, and Nucleotides in Psoriatic Arthritis Revealed by Unbiased Profiling of Serum Metabolites

Ananta Paine, Paul S. S. Brookes, Soumyaroop Bhattacharya, Dongmei Li, Maria De La Luz Garcia-Hernandez, Francisco Tausk, Christopher Ritchlin

Summary: We found differences in serum metabolites between PsA patients, psoriasis patients, and healthy controls. Differential abundance of bile acids, purines, pyrimidines, glutathione, lipids, and amino acid metabolites were observed in these three groups. Differences were also noted between psoriasis patients who progressed and those who did not progress to PsA. Decreased bile acid and butyrate levels and increased guanine levels in psoriasis patients at risk for PsA were particularly significant and may be reflective of gut microbial dysbiosis and dysregulated hepatic metabolism, leading to altered immune cell proliferation and enhanced cytokine expression.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Medicine, Research & Experimental

Thy-1 plays a pathogenic role and is a potential biomarker for skin fibrosis in scleroderma

Roberta G. Marangoni, Poulami Datta, Ananta Paine, Stacey Duemmel, Marc Nuzzo, Laura Sherwood, John Varga, Christopher Ritchlin, Benjamin D. Korman

Summary: Thy-1 expression is significantly increased in the skin of patients with systemic sclerosis and is correlated with the severity of skin involvement. Thy-1 plays a critical regulatory role in the onset and progression of skin fibrosis. Additionally, Thy-1 may serve as a biomarker for evaluating skin fibrosis.

JCI INSIGHT (2022)

Article Medicine, Research & Experimental

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Desiree van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P. Kollmeier, Proton Rahman

Summary: Guselkumab shows efficacy in reducing radiographic progression in patients with active PsA. The APEX trial further evaluates the impact of guselkumab on patients with active PsA and known risk factors for radiographic progression.

TRIALS (2023)

Review Rheumatology

The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?

H. Mark Kenney, Yue Peng, Karen L. de Mesy L. Bentley, Lianping Xing, Christopher T. Ritchlin, Edward M. Schwarz

Summary: Lymphatic muscle cell contractility and coverage are crucial for effective lymphatic drainage and tissue homeostasis. However, the fundamental role of these cells is still poorly understood due to their unique characteristics and difficulties in direct investigation. Further research is needed to uncover the origins, investiture, and maintenance of lymphatic muscle cells, as well as potential therapeutic strategies for controlling lymphatic contractility and drainage.

CURRENT RHEUMATOLOGY REVIEWS (2023)

Editorial Material Rheumatology

Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Tumor Necrosis Factor Inhibitor

Ying-Ying Leung, Arthur Kavanaugh, Christopher T. Ritchlin

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study

Christopher T. Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell

Summary: This study evaluated the efficacy and safety of guselkumab, an interleukin-23p19-subunit inhibitor, in patients with active psoriatic arthritis (PsA) who had previously used a tumor necrosis factor inhibitor (TNFi). The results showed that guselkumab provided sustained improvements across multiple domains in both TNFi-naive and TNFi-experienced patients with active PsA, and TNFi-naive patients were more likely to achieve treatment goals related to physical function and pain.

ACR OPEN RHEUMATOLOGY (2023)

Article Rheumatology

Bimekizumab treatment in biologic DMARD-na & iuml;ve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

Christopher T. Ritchlin, Laura C. Coates, Iain B. Mcinnes, Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B. M. Landewe

Summary: The long-term efficacy and safety of Bimekizumab (BKZ) in patients with psoriatic arthritis (PsA) was evaluated. The results showed that the efficacy of BKZ was sustained from Week 16 to Week 52, and patients who switched to BKZ treatment demonstrated similar efficacy to those who received BKZ continuously. BKZ treatment was well tolerated without any new safety signals.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention

Lihi Eder, Ker-Ai Lee, Vinod Chandran, Jessica Widdifield, Aaron M. Drucker, Christopher Ritchlin, Cheryl F. Rosen, Richard J. Cook, Dafna D. Gladman

Summary: The study aimed to develop a risk prediction model for psoriasis patients to predict their risk of developing psoriatic arthritis (PsA) and evaluate its performance. The results showed that using readily available clinical variables, the development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials

Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron

Summary: This study aimed to evaluate gene expression in the blood of patients with psoriatic arthritis (PsA) compared to healthy controls and identify changes associated with the treatment of guselkumab. The results showed dysregulation of immune cell profiles in the blood of PsA patients, which were partially normalized after guselkumab treatment.

ACR OPEN RHEUMATOLOGY (2023)

Article Rheumatology

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNFα inhibitor-experienced

Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Enrique R. Soriano, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Federico Zazzetti, Ramanand A. Subramanian, Xie L. Xu, Qing C. Zuraw, Shihong Sheng, Yusang Jiang, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, May Shawi, Chetan S. Karyekar, Atul Deodhar

Summary: The study demonstrated that guselkumab provided sustained improvement in patients with Psoriatic Arthritis, maintaining a favorable benefit-risk profile regardless of prior TNFi exposure.

RMD OPEN (2021)

暂无数据